Polyrizon Ltd.
PLRZHealthcare|Biotechnology|IL
$11.04
-0.55 (-4.70%)
DCF Value
$0.81
Tangible Book / Share
$12.17
Cash / Share
$8.31
Clinical Trials (1)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07588672 Evaluation of the Efficacy, Safety, and Tolerability of PL-14 Allergy Blocker Compared to Saline Spray in Patients With Seasonal Allergic Rhinitis | Seasonal Allergic Rhinitis (SAR), Allergic Rhinitis | N/A | Recruiting | 120 | RCT, Single-blind | — |